BRIEF-Oncosec announces positive phase II data for Immunopulse IL-12 in combination with pembrolizumab

* Oncosec announces positive phase ii data demonstrating

company's Immunopulse IL-12 in combination with pembrolizumab

increased response rates in anti-PD-1 non-responder melanoma

patients

Read more